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S196 Poster Session I(logrank p 5 0.003), and 89% for IPS score 5 0-1, 56% for IPS 5
2-3, and 24% for IPS 5 4-7 (logrank p\ 0.001). Response to DI-
CEP and relapse IPS were the only two factors that independently
predicted PFS and OS in multivariate analysis. Of the 26 patients
who relapsed following DICEP6HDM/ASCT, 7 (27%) achieved
subsequent long-term PFS of $ 3 years using radiotherapy
(n 5 1), chemotherapy and radiotherapy (n 5 2), or allogeneic
SCT (n 5 4).
DICEP-HDM/ASCT for relapsed/refractory Hodgkin lym-
phoma is associated with excellent stem cell mobilization capability
and favourable PFS and OS outcomes. These results compare
favourably to previously reported alternative regimens and require
validation in a prospective multi-centre clinical trial.115
ANOVEL HIGHDOSE CHEMOTHERAPY STRATEGYWITH BENDAMUSTINE
IN ADJUNCT TO ETOPOSIDE, CYTARABINE AND MELPHALAN (BEEAM)
FOLLOWED BY AUTOLOGOUS STEM CELL RESCUE IS SAFE AND HIGHLY
EFFECTIVE FOR THE TREATMENT OF RESISTANT/RELAPSED LYMPHOMA
PATIENTS: A PHASE I-II STUDY ON 44 PATIENTS
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BEAM (Carmustine, etoposide, cytarabine, and melphalan) is the
most used conditioning regimen before autologous stem cell trans-
plant (ASCT) in lymphoma patients. However, relapse rate after
transplant is still a matter of concern. Therefore, new regimens
with a higher efficacy are particularly needed.
We designed a phase I-II study to evaluate the safety and the effi-
cacy of increasing doses of Bendamustine for the conditioning regi-
men to ASCT for resistant/relapsed lymphoma patients. As
a biological background, we performed in vitro experiments which
showed the synergistic activity of bendamustine with etoposide, ara-
cytin and melphalan in lymphoma cell lines.
Forty-four patients (median age 47 years) with resistant/relapsed
non-Hodgkin (29) or Hodgkin (15) lymphoma were consecutively
enrolled in the study. The new regimen consisted of increasing doses
of Bendamustine coupled with fixed doses of Etoposide (200mg/m2/
day on days -5 to -2), Cytarabine (400mg/m2 on days -5 to -2) and
Melphalan (140 mg/m2 on day -1) (BeEAM regimen). The study
was registered at EMEA with the EUDRACT no 2008-002736-
15. The starting dose of Bendamustine was 160 mg/m2/daily given
on days -7 and -6, which was then escalated according to the Fibo-
nacci’s increment rule until the onset of severe adverse events and/
or the attainment of the expected MTD, but not higher than 200
mg/m2.
The administration of Bendamustine was safe in all the 3 cohorts
of 3 patients. We then fixed the dose of Bendamustine 200 mg/m2 as
safe and effective for the Phase II study.
A median number of 5.68x106CD341/kg cells (range 2.4-15.5) col-
lected from peripheral bloodwas reinfused to patients. All patients en-
grafted, with a median time to ANC . 0.5x109/l of 10 days. Median
times to achieve a platelet count . 20x109/l and . 50x109/l were 13
and16days respectively.Twenty-twoout of 44 patients presented a fe-
ver of unknown origin. All patients received G-CSF after transplant
for a median time of 9 days (range: 8-25).
39/44 patients are evaluable for the response to treatment. After
a median follow-up of 14 months from transplant, 32/39 patients
are in complete remission, whereas 4/39 are in partial response. 3/
39 patients relapsed after a median time of 3 months from transplant.
Remarkably, 4/39 patients achieved the first complete remission af-
ter receiving the high-dose therapy with ASCT.
In conclusion, the new BeEAM regimen is safe and seems to have
a high efficacy in heavily pretreated lymphoma patients.116
NORDIC MCL2 TRIAL OF 1ST-LINE INTENSIVE IMMUNOCHEMOTHERAPY
AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN MANTLE CELL
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Mantle cell lymphoma (MCL) has a poor prognosis with a median
survival of 5 years based on conventional immunochemotherapy. In
spite of the high risk characteristics of the 160 patients of the Nordic
MCL2 Trial of 1.-line intensive immunochemotherapy followed by
BEAM and autologous stem cell transplantation (31% with high Ki-
67 expression, 19% blastoid/pleomorphic), the first results based on
three years median observation were encouraging, including no re-
lapses after 5 years1. In the present update based on median 5.6 years
observation, the 10-year overall survival (OS) is 58%. Late relapses
have decreased the 10-year event-free survival (EFS) and response
duration (RD) to 35% and 46%, respectively. An example of a late
relapse was an isolated CNS relapse in a patient otherwise in persis-
tent complete remission 9.5 years after initial treatment. The mantle
cell lymphoma International prognostic index (MIPI)2, previously
found of prognostic value in our cohort3, remained highly predictive
of OS, EFS and RD. Particularly theMIPI-biological, incorporating
Ki-67, identified 20% of the patients still relapse-free from 3.4 years
to now 9 years posttransplant. Amolecularmarker was available in 71
of the 145 responding patients who completed treatment and had
follow-up samples for minimal residual disease. Molecular response
duration of less than one year posttransplant corresponded to
a shorter clinical response duration (median 4.2 years) than molecu-
lar response duration . 1 year (median 9 years clinical response
duration). In conclusion, the 58% 10-year survival of this high-risk
cohort is still very encouraging, but late relapses do occur, warrant-
ing long-term control and trials of maintenance treatment in this
disease.
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MINIMIZING THE COST OF CURRENT INEFFECTIVE MOBILIZATIONS:
DOUBLING FILGRASTIM ON DAY 4 OF FILGRASTIM-ALONE MOBILIZA-
TION FOR AUTOLOGOUS PERIPHERAL STEM CELL COLLECTION
REDUCES THE USE OF PLERIXAFOR
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Background: Autologous stem cell mobilization with colony stimu-
lating factors alone has a failure rate of approximately 20%. Plerixa-
for is a stem cell mobilizer effective in increasing the number of
peripheral CD34 cells collected by hematopoetic progenitor cell
apheresis (HPC-A) while reducing the number of HPC-A days in
Poster Session I S197autologous patients that failed prior collection attempts with filgras-
tim (G-CSF) alone. Many centers use plerixafor for prior failed
mobilization on the evening of day 4 of G-CSF. Less consensus
regarding the utilization and timing of plerixafor with current inef-
fective mobilization exists. We developed a strategy utilizing dou-
ble-dose G-CSF on day 4 if the CD34 count was less than 10
cells/mL in an attempt to increase the CD34 count to sufficient levels
to initiate HPC-A, thus obviating the need for plerixafor.
Methods: All patients undergoing HPC-A collections from April
2009 to May 2010 were reviewed. The predefined protocol was as
follows:
All patients started G-CSF 10mcg/kg SQ on day 1.
CD34 cell counts were drawn day 4 of G-CSF.
 If the CD34 cell count $ 10, proceed with HPC-A.
 If\10, an additional evening dose ofG-CSF10mcg/kgwas added.
CD34 cell counts repeated day 5.
 If$ 10, proceedwithHPC-A and continue twice dailyG-CSF un-
til the desired CD34 count.
 If the count 1 to 9, G-CSF revert back to once daily and plerixafor
was added the evening of day 5 with HPC-A the next morning.
 If\ 1, the mobilization attempt was deemed a failure.
Minimum collection goal was 3  106/kg CD34.
Results: 86 patients underwent stem collection, of which 69 fol-
lowed our G-CSF-alone protocol. All 69 were successfully mobi-
lized, 41 (59%) with G-CSF 10mcg/kg SQ daily alone. Of the
remaining 28, 18 (64%) mobilized with twice daily G-CSF and 10
(36%) required plerixafor.
Table 1.
MeanN
Mean
CD34/kg
Mean
HPC-A Days
Cost per
Mobilzation*Daily G-CSF alone 41 8.15 1.98 $14,757
BID G-CSF 18 6.35 3.17 $23,724
Plerixafor + G-CSF 10 6.45 2.80 $35,863*HPC-A cost of $6000/day and hospital acquisition cost utilized for
G-CSF and plerixafor.Cost savings utilizing our strategy versus plerix-
afor on day 4 was $219,000 including drug and HPC-A procedure
costs.This translates to a cost savings of approximately $8,000per pa-
tient.
Conclusion: Doubling the G-CSF frequency to twice daily on day 4
when theCD34 countwas 1- 10was effective inmobilizing 64%of pa-
tients who failed G-CSF-alone mobilization in a similar number of
HPC-Adays (3.17 vs 2.80) when compared to plerixafor. This strategy
results in a significant cost avoidance of approximately $8,000 per pa-
tient. Consideration should be given to double-dose G-CSF on day 4
of current ineffective mobilization in lieu of plerixafor.118
PRELIMINARY EXPERIENCE WITH PLERIXAFOR FOR PERIPHERAL
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Autologous peripheral blood stem cell (PBSC) transplant is an ac-
cepted therapy for pediatric patients with lymphoma, neuroblas-
toma, and CNS tumors. PBSC mobilization with filgrastim alone
or filgrastim following chemotherapy may be unsuccessful in heavily
pretreated patients, based on a desired minimum cell count of 2x
10E6 CD341/kg to proceed with Autologous PBSC transplant.
Plerixafor is approved for use in combination with filgrastim for
PBSCmobilization, and in adults with lymphoma or myeloma, pler-
ixafor/filgrastim mobilization results in 2- to 3-fold increased likeli-
hood of successful harvest compared to filgrastim alone. We report
our experience with plerixafor, utilizing a dose of 240 micrograms/
kg SQ 10 -11 hours before pheresis, repeated daily up to 4 days, in7 pediatric patients (3 refractory Burkitt lymphoma (BL), 1 high
risk neuroblastoma (NB), 2 medulloblastoma (MB), 1 recurrent
CNS PNET), ages 10 to 20 years, with inadequate or borderline
PBSC yields following multiagent chemotherapy and filgrastim. In-
cremental PBSC yields following filgrastim and plerixafor were 0 to
9.0  10E6 CD341 cells/kg. The Peripheral Blood CD341 counts
varied widely from . 1.0 to 56 cells/uL. 2 of 3 BL patients and the
NB patient mobilized successfully and underwent autotransplant. 1
BL patient failed to mobilize and underwent allogeneic transplant.
Of 3 CNS tumor patients (all with prior craniospinal irradiation),
1 with MB and 1 with PNET had successful mobilization but died
of disease progression prior to autotransplant; the other patient
with MB continues on reinduction chemotherapy. No serious ad-
verse events were seen.We conclude that plerixafor is safe and effec-
tive in selected pediatric patients even following craniospinal
irradiation, butmay be less effective in refractory patients with exten-
sive prior chemotherapy. The latter group could potentially benefit
from earlier introduction of plerixafor at the first attempted PBSC
mobilization.119
DEFIBROTIDE PREVENTS THE ACTIVATION OF MACROVASCULAR AND
MICROVASCULAR ENDOTHELIA CAUSED BY THE SOLUBLE FACTORS RE-
LEASED TO BLOOD BY AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION
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Endothelial activation and damage occur in association with autol-
ogous hematopoietic stem cell transplantation (HSCT). Several of
the early complications associated withHSCT seem to have amicro-
vascular location. Through the present study, we have characterized
the activation and damage of endothelial cells of both macro
(HUVEC) and microvascular (HMEC) origin, occurring early after
autologous HSCT, and the potential protective effect of defibrotide
(DF). Sera samples from patients were collected before conditioning
(Pre), at the time of transplantation (day 0), and at days 7, 14 and 21
after autologous HSCT. Changes in the expression of endothelial
cell receptors at the surface, presence and reactivity of extracellular
adhesive proteins, and the signaling pathways involved were
analyzed. The expression of ICAM-1 at the cell surface increased
progressively in both HUVEC and HMEC. However, a more pro-
thrombotic profile was denoted for HMEC, in particular at the
time of transplantation (day 0), reflecting the deleterious effect of
the conditioning treatment on the endothelium, especially at amicro-
vascular location. Interestingly, this observation correlated with
a higher increase in the expression of both tissue factor and vonWil-
lebrand factor on the extracellular matrix, together with activation of
intracellular p38 MAPK and Akt. Previous exposure and continuous
incubation of cells with DF prevented the signs of activation and
damage induced by the autologous sera. These observations corrob-
orate that conditioning treatment in autologous HSCT induces
a proinflammatory and a prothrombotic phenotype, specially at
a microvascular location, and indicate that DF has protective antiin-
flammatory and antithrombotic effects in this setting.120
EFFICACY AND COST-BENEFIT ANALYSIS OF PLERIXAFOR PLUS
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Plerixafor (P) in combination with filgrastim (F) is currently ap-
proved for mobilization of hematopoietic progenitor cells (HPC) in
patients with multiple myeloma (MM) or non-hodgkin’s lymphoma
(NHL). F1 P is a very expensive but reduces the incidence of mobi-
lization failure. In an effort to utilize P in a cost efficient manner, we
employed a risk adaptive strategy of using P only in patients who are at
high risk of mobilization failure defined by peripheral blood CD341
